Drug Trial Radar · NCT06194318
First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults
Last checked: Nov 19, 2026Latest source record: Jun 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
160
Actual
Start
Dec 13, 2023
Primary completion
Feb 26, 2025
Study completion May 7, 2025
Sponsor
- Lead sponsor
- Clover Biopharmaceuticals AUS PtyIndustry
- Sponsor type
- Industry
- First posted
- Jan 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults
Conditions
- Respiratory Syncytial Virus Vaccination
Interventions
Candidate vaccine, SCB-1019Biological
The SCB-1019 vaccine contains RSV F protein subunits from the two dominant circulating strains, A strain (SCB-1019A) and B strain (SCB-1019B). SCB-1019A and SCB-1019B are recombinant RSV F-Trimer proteins engineered by fusing the ectodomain of RSV F protein with Trimer-Tag™
placeboBiological
placebo
candidate vaccine, SCB-1019TBiological
The SCB-1019T vaccines contain RSV F protein subunits from the two dominant circulating strains, A and B strain. Antigens are recombinant RSV F-Trimer proteins engineered by fusing the ectodomain of RSV F protein with Trimer-Tag™
AREXVYBiological
AREXVY is a FDA-approved respiratory syncytial virus (RSV) vaccine for adults aged 60 and older. Developed by GSK, it targets the prefusion F glycoprotein to protect against lower respiratory tract disease caused by RSV.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the reactogenicity of SCB-1019, SCB-1019T compared with AREXVY vaccineTime frame: Within 7 days after vaccination
- Evaluate the safety tolerability of SCB-1019, SCB-1019T compared with AREXVY vaccineTime frame: Within 28 days after vaccination
- Evaluate the safety and tolerability of SCB-1019, SCB-1019T compared with AREXVY vaccineTime frame: Throughout the study period, from enrollment to 6 months follow up
- Evaluate the safety and tolerability of SCB-1019, SCB-1019T compared with AREXVY vaccineTime frame: Screening and Day 8
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Fusion Clinical Research
Adelaide, Southern Australia, Australia
Linear Clinical Research
Nedlands, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.